Wealth Enhancement Advisory Services
CTKB icon

Wealth Enhancement Advisory Services’s Cytek Biosciences CTKB Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$222K Sell
61,873
-10,827
-15% -$46.2K ﹤0.01% 3494
2026
Q1 		$260K Buy
72,700
+36,975
+103% +$175K ﹤0.01% 2912
2025
Q4 		$202K Sell
35,725
-650
-2% -$3.02K ﹤0.01% 3265
2025
Q3 		$138K Buy
36,375
+5,308
+17% +$19.9K ﹤0.01% 3258
2025
Q2 		$117K Buy
31,067
+15,351
+98% +$51.2K ﹤0.01% 3115
2025
Q1 		$63K Buy
+15,716
New +$81.5K ﹤0.01% 2833

Other funds holding CTKB

YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
NAM
NorthCrest Asset Manangement Plymouth, Minnesota $3.89B AUM 40.33% 1-Year Est. Return
EFG
Everhart Financial Group Dublin, Ohio $1.56B AUM 34.29% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.12B AUM 34.21% 1-Year Est. Return
DCM
Davis Capital Management Jacksonville, Florida $169M AUM 22.99% 1-Year Est. Return

Wealth Enhancement Advisory Services's CTKB Position: Q2 2026 in Review

Wealth Enhancement Advisory Services reduced its Cytek Biosciences (CTKB) stake by 15% in Q2 2026, selling an estimated $46.2K and leaving 61,873 shares worth $222K. The position accounts for ﹤0.01% of the portfolio, ranked #3494.

Wealth Enhancement Advisory Services first reported a position in CTKB in Q1 2025 and has held it in 6 quarters since. The position peaked at $260K in Q1 2026. 8 funds tracked by Wall St. Rank hold CTKB as of Q2 2026.

  • Wealth Enhancement Advisory Services held 61,873 shares of Cytek Biosciences worth $222K as of Q2 2026.
  • Wealth Enhancement Advisory Services sold 10,827 Cytek Biosciences shares in Q2 2026, an estimated $46.2K.
  • Cytek Biosciences made up ﹤0.01% of Wealth Enhancement Advisory Services's portfolio in Q2 2026, its #3494 holding.
  • Wealth Enhancement Advisory Services first reported a position in Cytek Biosciences in Q1 2025 and has held it in 6 quarters since.
  • Wealth Enhancement Advisory Services's Cytek Biosciences position peaked at $260K in Q1 2026.
  • 8 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q2 2026, filed 15 Jul 2026.